Cystic Fibrosis (CF) Clinical Trial
Official title:
Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Urine After a Short Pause of Therapy
In cystic fibrosis (CF) renal base excretion is impaired, due to mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, since CFTR function is crucial in regulation of the kidney's HCO3- excretion. The investigators suggest that challenged urine HCO3- excretion is a biomarker of CFTR function, which can be used to evaluate the extent of CFTR dysfunction and the possible correcting effects of CFTR modulating therapy. This study aims to evaluate changes in challenged urine HCO3- excretion in CF patients, who are currently in treatment with the triple CFTR modulator combination therapy, Elexacaftor/tezacaftor/ivacaftor (ETI), before, during, and after a short treatment pause.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04853368 -
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
|
Phase 2 | |
Terminated |
NCT03234387 -
A CFit Study - Baseline
|
||
Completed |
NCT03445793 -
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
|
||
Completed |
NCT02778750 -
Evaluation Of The Pan-microbiome and Host Immune Response in CF
|
||
Completed |
NCT00677365 -
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
|
Phase 2 | |
Terminated |
NCT03597347 -
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
|
Phase 2 | |
Completed |
NCT04375878 -
OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
|
Phase 2 | |
Withdrawn |
NCT01951833 -
Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis
|
N/A | |
Completed |
NCT03746483 -
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 2 | |
Completed |
NCT02163681 -
MRI for Non-Invasive Imaging in Neonates and Children
|
N/A | |
Completed |
NCT02036879 -
Gender Disparity and Hormones in Cystic Fibrosis
|
Early Phase 1 | |
Completed |
NCT02605590 -
Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT01851642 -
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
|